Amgen (AMGN) stock is back in focus after the company beat Wall Street expectations in its second quarter 2026 report and raised full year revenue and earnings guidance, citing broad based, volume driven product strength.

Against this backdrop of raised guidance and steady product news, Amgen’s share price has shown firm upward momentum, with a 90 day share price return of 17.79% and a 1 year total shareholder return of 33.88%. This performance supports a stronger long run picture for patient investors.

If Amgen’s recent move has you thinking about where else growth and new treatments could emerge in healthcare, it could be worth scanning for opportunities among 41 healthcare AI stocks.

After Amgen’s sharp re-rating, the stock now sits above the average analyst target yet screens at a sizeable intrinsic discount. Is the market being too cautious on the risks around data, regulation and cyber breaches, or not cautious enough?

Most Popular Narrative: 8.3% Overvalued

Amgen closed at $390.02 while the most followed narrative pegs fair value closer to $359.98. That gap sets up a clear debate on what the current price is baking in.

The "Amgen 2027 Bull Case" relies on a classic top-line fallacy: assuming that macro obesity market growth and FDA's CNPV (Commissioner’s National Priority Voucher) tailwinds will automatically trigger a re-rating.

Here is the cold, data-driven reality:

Curious what sits under that $359.98 fair value for Amgen. The narrative leans heavily on specific revenue growth, profit margins and a future earnings multiple that has to line up just right. Want to see which of those inputs is doing most of the heavy lifting.

Result: Fair Value of $359.98 (OVERVALUED)

However, Amgen could still surprise if obesity data exceed expectations or if regulatory uncertainty around the CNPV program eases faster than the market currently assumes.

Another View On Amgen’s Valuation

The narrative driven fair value of $359.98 paints Amgen as 8.3% overvalued. Yet our DCF model points a different way, with Amgen trading at $390.02 compared with an estimated future cash flow value of $667.88. That implies a large upside gap. Which story do you trust more: the narrative inputs or the cash flow math?

Next Steps

With mixed signals across Amgen’s valuation stories, it makes sense to move quickly, review the underlying data for yourself and weigh both sides. To help frame that view, start with the 3 key rewards and 1 important warning sign.

Looking for more Amgen style investment ideas?

If you stop with Amgen, you risk missing other stocks that fit your goals. Put the Simply Wall Street Screener to work and broaden your opportunity set today.

• Target stability first and check out companies with resilient balance sheets and steady fundamentals through the solid balance sheet and fundamentals stocks screener (49 results).
• Hunt for quality at a reasonable price by scanning for companies that look mispriced on fundamentals with the 52 high quality undervalued stocks.
• Build a shortlist of less followed opportunities by using the screener containing 18 high quality undiscovered gems before the wider market catches on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.